Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Spring Break: Novo's US Head Resigns After Rough Winter

Executive Summary

Novo Nordisk's executive VP and head of North American operations, Jakob Riis, has resigned from the company – a move not completely out of the blue considering recent rumors of conflict within the diabetes drug developer's US operations and a lackluster 2016 financial performance for the whole group.

You may also be interested in...



US Insulin Pricing Probe Clouds Prospects for Novo Nordisk, Others

As US prosecutors investigate Novo Nordisk and other insulin makers for their pricing and contracts with pharmacy benefit managers, plaintiff firms allege the Danish group engaged in collusive agreements and misled investors about its earnings and forecasts.

Novo Nordisk Names Jørgensen CEO As Sørensen Steps Down Early

Lars Rebien Sørensen is retiring as CEO of Novo Nordisk by the end of the year, with executive vice president and corporate development head Lars Fruergaard Jørgensen stepping up as his successor.

PROFILE: Novo's Riis Recalls First Victoza Delivery, Growing Up With Science

Jakob Riis is a Danish national who joined diabetes R&D giant Novo Nordisk in 1996 as a health economist. He has since risen through the company, via a series of marketing roles of increasing seniority, to take on his current position of executive vice-president of China, Pacific and marketing.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132466

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel